The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
J-TAIL-2: A prospective observational study of atezolizumab (atezo) combination therapy in patients (pts) with non-small cell lung cancer (NSCLC) in Japan.
 
Yasutaka Watanabe
No Relationships to Disclose
 
Makoto Nishio
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Eisai; Janssen; Lilly; Merck; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Kadoaki Ohashi
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Kyowa-Kirin; Lilly; MSD; Nippon Kayaku; Novartis
Research Funding - Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Lilly
 
Atsushi Osoegawa
Honoraria - AstraZeneca; Chugai Pharma; Ono Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma
Speakers' Bureau - AstraZeneca; Chugai Pharma; MSD Oncology; Ono Pharmaceutical
 
Eiki Kikuchi
No Relationships to Disclose
 
Hideharu Kimura
No Relationships to Disclose
 
Yasushi Goto
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/UCB Japan; Guardant Health AMEA; Janssen; Lilly Japan; Merck; MSD; Nichiiko; Novartis; Ono Pharmaceutical; Pfizer; Sandoz; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; Guardant Health AMEA; Janssen; Lilly; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Amgen BioPharama (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo/UCB Japan (Inst); EP Croit Co. (Inst); EPS Holdings (Inst); Genomic Health (Inst); IQvia (Inst); Janssen (Inst); Lilly Japan (Inst); Medpace (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Preferred Network (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
(OPTIONAL) Uncompensated Relationships - Cancer Net Japan; JAMT
 
Junichi Shimizu
Speakers' Bureau - Amgen; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Merck; MSD Oncology; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Eisaku Miyauchi
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Meyers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Kyorin; Kyowa Kirin; Kyowa Kirin Co Ltd; Lilly; Merck; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - Boehringer Ingelheim; Daiichi Sankyo KK; Merck; Ono Pharmaceutical
 
Hiroshige Yoshioka
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Delta-Fly Pharma; Lilly; Merck; MSD K.K; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Delta-Fly Pharma
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Delta-Fly Pharma (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst)
 
Ichiro Yoshino
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Covidien/Medtronic; Daiichi Sankyo; Intuitive Surgical; Johnson and Johnson; Shionogi; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Medicaroid
Research Funding - Chugai Pharma (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Toshihiro Misumi
Honoraria - Chugai Pharma; Miyarisan pharmaceutical
 
Masafumi Yamaguchi
Speakers' Bureau - AstraZeneca Japan; Bristol-Myers Squibb K.K.; Chugai Pharma; Lilly; MSD K.K.
 
Kouzou Yoshimori
No Relationships to Disclose
 
Masahiro Seike
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Daiichi-Sankyo Company; Kyowa Hakko Kirin; Lilly; Merck; MSD K.K; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma; Kyowa Hakko Kirin; Lilly; Nippon Boehringer Ingelheim; Nippon Kayaku; Taiho Pharmaceutical
 
Hironori Yoshida
Honoraria - Chugai Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., AstraZeneca K.K., MSD. K. K, Bristol-Myers Squibb Co. Ltd.
Speakers' Bureau - Chugai Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., AstraZeneca K.K., MSD. K. K, Bristol-Myers Squibb Co. Ltd.
Research Funding - Chugai Pharma
 
Kazumi Nishino
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Janssen; Lilly Japan; Merck; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca; Lilly Japan; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); Bayer Pharma Japan. (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Eisai (Inst); Gilead Sciences (Inst); Janssen (Inst); Lilly Japan (Inst); Merck (Inst); Merus (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Asako Miwa
Employment - Chugai Pharma
Stock and Other Ownership Interests - Chugai Pharma
Travel, Accommodations, Expenses - Chugai Pharma
 
Misa Tanaka
Employment - Chugai Pharma
Stock and Other Ownership Interests - Chugai Pharma
Honoraria - Kowa Pharmaceutical (I)
 
Akihiko Gemma
Consulting or Advisory Role - Nihonkayaku
Speakers' Bureau - Daiichi Snkyo